Evaluation of the STAT3 inhibitor, SH-4-54, as a possible treatment to decrease GBM migration, reduced the migration ability of GBM43 in a 3D microenvironment but had no effect on the cell line GBM10 despite both cell lines present wildtype STAT3. Here, STAT3 is linked to glioblastoma.